1.Effect of transrectal prostatic biopsy on serum prostate specific antigen levels.
Ze-Qiao XU ; Li-Xin HUA ; Li-Xin QIAN ; Hong-Fei WU
National Journal of Andrology 2002;8(5):341-342
OBJECTIVESTo assess the effect of transrectal prostatic biopsy (TPB) on the concentrations of serum prostate specific antigen (PSA).
METHODSTwenty patients with abnormal PSA levels and/or digital rectal examination (DRE) underwent TPB. Serum PSA levels were measured before TPB and at 0.5 h, 1 week, 1 month after TPB, respectively.
RESULTSThe serum PSA levels before TPB and 0.5 h, 1 week, 1 month after TPB were (12.23 +/- 8.62), (34.90 +/- 41.53), (23.59 +/- 20.78) and (11.31 +/- 6.95) micrograms/L, respectively. The serum PSA concentration was significantly higher at 0.5 h after TPB than before (P < 0.05), and then gradually decreased. PSA levels remained higher for at least 1 week in 85% (17/20) patients(P < 0.05), then returned to the baseline at one month after TPB (P > 0.05).
CONCLUSIONSTPB can lead to a dramatic increase of PSA in serum and keep the PSA value high in one week. Then the PSA in serum decreased gradully. Serum PSA level cannot return to baseline until one month after TPB.
Biopsy ; Humans ; Male ; Prostate ; pathology ; Prostate-Specific Antigen ; blood
2.Multi-institutional randomized controlled clinical trial on China made 4-demethoxydaunokrubicin (IDA) in the treatment of acute leukemia.
Yan LIU ; Xiao-yan KE ; Jun MA ; Zhi-xiang SHEN ; Xiao-hong ZHANG ; Xin DU ; Yi-ming ZHAO ; Jing-qiao LÜ ; Zhao-min ZHAN ; Xiao-ying ZENG ; Xiao-hua XU ; Ze-sheng LU
Chinese Journal of Oncology 2005;27(12):750-752
OBJECTIVETo evaluate the efficacy and safety of IDA (Haizheng Parmacy, China) in the treatment of acute leukemia.
METHODSA multi-institutional single-blind randomized controlled clinical trial was carried out. A total of 155 newly diagnosed patients with AML and ALL were enrolled. The patients were randomly divided into two groups, one was given IDA (n = 77) and the other given zevodas (Pharnacia & Upjohn, n = 78) for comparison.
RESULTSAll the patients enrolled in this trial were eligible for assessment of side effects, and 129 patients for evaluation of overall response rate. In patients treated with IDA vs zevodas, the overall response rate (OR) was 78.1% vs 76.9%, CR was 68.8% vs 67.7%; in AML patients, OR was 82.4% vs 71.8%, and CR was 76.5% vs 64.1%; in ALL patients, OR was 80.0% vs 81.8%, and CR was 68.0% vs 68.2%. There was no sitatistically significant difference in hematologic and non-hematologic toxicities between the two groups.
CONCLUSIONThe efficacy of IDA in the treatment of acute leukemia is comparable to that of zevodas. Both have similar toxic side effects.
Adolescent ; Adult ; Aged ; Antibiotics, Antineoplastic ; adverse effects ; therapeutic use ; China ; Female ; Humans ; Idarubicin ; adverse effects ; therapeutic use ; Leukemia, Myeloid, Acute ; drug therapy ; Male ; Middle Aged ; Precursor Cell Lymphoblastic Leukemia-Lymphoma ; drug therapy ; Single-Blind Method
3.Multicenter randomized control trial on safety of domestic idarubicin for acute leukemia.
Yan LIU ; Xiao-yan KE ; Jun MA ; Zhi-xiang SHEN ; Xiao-hong ZHANG ; Xin DU ; Yi-ming ZHAO ; Jing-qiao LV ; Zhao-min ZHAN ; Xiao-ying ZENG ; Xiao-hua XU ; Ze-sheng LU
Chinese Journal of Oncology 2006;28(9):706-708
OBJECTIVETo evaluate the safety of domestically produced idarubicin in the treatment of acute leukemia by a multicenter randomized control trial.
METHODSThis trial was carried out in the hemotologica department of five hospitals throughout China, with hospitalized patients who suffered from acute myelogenous leukemia ( AML except M3 type) , acute lymphocytic leukemia ( ALL) , chronic myelogenous leukemia-blast (CML-blast) , totally 155 patients. Those with severely cardial, hepatic or renal disfunction or those who had ever treated with > or = 200 mg/m(2) idarubicin were excluded from the trial. All patients signed the letter of consent as required by the Ethics Committee of our government. In this study, 155 leukemia patients were randomly grouped into: 1. test group treated using domestic idarubicin, 2. control group using imported idarubicin. The acute myelogenous leukemia regimen included idarubicin 8 mg/m(2), dl -3 plus cytosine arabinoside 100 mg/m(2), dl - 7 for 1-2 cycles. The regimen for acute lymphocytic leukemia was idarubicin 8 mg/m2, dl - 3; vincristine 2 mg/mr, dl; cyclophosphamide 750 mg/m2, dl ; plus prednisone 60 mg/m(2),dl - 14 for 1-2 cycles.
RESULTSClinical response rate of the tested group treated with domestic idarubicin and control group treated with imported idarubicin was 78. 1% (50/64) vs. 76.9% (50/65) without any statistically significant difference between the two groups(P >0. 05). Grade Ill - IV hematological toxicity rate of the domestic idarubicin group and imported idarubicin group was 74. 0% vs. 73. 1% , respectively (P = 0. 73). Drug-related death was observed in 3 of 77 patients in the domestic idarubicin group (3.9%) due to cerebral hemorrage or septic infection. The incidence of non-hematological toxicities in domestic idarubicin group and imported idarubicin group was 84. 4% vs. 79. 5% for nausea or vomiting, 70. 1% vs. 71. 8% for infection, 42. 9% vs. 41. 0% for mucositis, 33. 8% vs. 33. 3% for alopecia, 28.6% vs. 28. 2% for serum glutamicoxalacetic transaminase abnormalitis, 16. 9% vs. 10. 3% for cardiac toxicity, all without statistically significant differences between these two groups (P > 0. 05). Discontinuation of treatment due to non-hematological toxicity was not neccessary.
CONCLUSIONDomestic idarubicin is comparable to imported counterpart in efficiency and safety for the treatment of acute leukemia. The most severe side effects of domestic idarubicin is hematological toxicity, which should be closely observed and treated in time, while its non-hematological toxicity is tolerable.
Adolescent ; Adult ; Aged ; Agranulocytosis ; chemically induced ; Antibiotics, Antineoplastic ; administration & dosage ; adverse effects ; Antineoplastic Combined Chemotherapy Protocols ; adverse effects ; therapeutic use ; Blast Crisis ; drug therapy ; Cyclophosphamide ; administration & dosage ; adverse effects ; Cytarabine ; administration & dosage ; adverse effects ; Female ; Humans ; Idarubicin ; administration & dosage ; adverse effects ; Leukemia, Myeloid, Acute ; drug therapy ; Male ; Middle Aged ; Mucositis ; chemically induced ; Nausea ; chemically induced ; Precursor Cell Lymphoblastic Leukemia-Lymphoma ; drug therapy ; Prednisone ; administration & dosage ; adverse effects ; Remission Induction ; Treatment Outcome ; Vincristine ; administration & dosage ; adverse effects
4.A prospective multicenter clinical trial of medical and surgical treatment for chronic rhinosinusitis.
Dilidaer DILIDAER ; De-Hui WANG ; Li SHI ; Hua ZHANG ; Li QIAO ; Shi-Xi LIU ; Ze-Zhang TAO ; Bei-Bei YANG ; Jie DENG ; Geng XU
Chinese Journal of Otorhinolaryngology Head and Neck Surgery 2013;48(9):734-740
OBJECTIVETo demonstrate the clinical outcomes of maximal medical therapy(MMT) and functional endoscopic sinus surgery+ maximal medical therapy (FESS+MMT) for moderate to severe chronic rhinosinusitis without nasal polyps (CRSsNP) in China, to provide clinical evidence for treatment recommendation.
METHODSA prospective multicenter case control study consisting of 90 strictly selected CRSsNP patients were carried out by ENT Hospital of SUN Yet-sen university and 7 other university affiliated hospitals across China from March 2011 to October 2012. All patients were selected to MMT group or FESS+MMT group followed by 3 months treatment and 6 months follow up. Treatment efficacy evaluation indicators included improvement of visual analogue scale (VAS) score, quality of life, CT score and post-operative nasal endoscopic evaluations. SPSS16.0 software was used to analyze the data.
RESULTSAll patients enrolled complied with moderate to severe CRSsNP evaluation criteria. There were no significant differences found in the baseline data between two groups (P > 0.05). (1) At the 3 time points (pre-treatment, 3 months and 6 mongths after treatment) , VAS overall symptom score in MMT group were 6.52 ± 2.61, 2.66 ± 2.10, 2.40 ± 1.56, significant differences were found among them (t value were 2.083 and 2.295, both P < 0.05); in FESS+MMT group the values were 6.99 ± 2.70, 0.95 ± 0.84, 0.60 ± 0.81, significant differences were found among them (t value were 3.582 and 5.196, both P < 0.05); SNOT-20 score in MMT group were 38.61 ± 17.36, 18.59 ± 14.04, 18.40 ± 8.91, significant differences were found among them (t value were 2.737 and 2.657, both P < 0.05); in FESS+MMT group the values were 38.21 ± 19.61, 5.94 ± 5.01, 2.65 ± 2.31, significant differences were found among them (t value were 3.247, 3.319, both P < 0.05). (2) FESS+MMT group relative to the MMT group in VAS overall symptom score and quality of life improvements appeared earlier and were more pronounced. (3) Overall treatment efficacy showed that in MMT group: complete control 14 cases (30.4%), partially control 31 cases (67.4%), uncontrolled 1 cases (2.2%); In FESS+MMT group: complete control 17 cases (38.6%), partially control 26 cases (59.1%), uncontrolled 1 cases (2.3%). (4) Patients' satisfaction survey showed that the number of the patients who were very satisfied with the efficacy in the FESS+MMT group were 2 times higher than the MMT group.
CONCLUSIONS(1) For moderate to severe CRSsNP, both MMT and FESS+MMT treatment can effectively control the overall symptoms and classified symptoms, reduce CT scores and significantly improve the quality of life, the ineffective rate is less than 5%. (2) FESS+MMT group in terms of improving symptoms and the onset time are better than MMT group, especially in improving the stuffy nose, head and face fullness, and mental and physical symptoms are better than MMT group. (3) FESS+MMT group showed better results in patient satisfaction survey compared to the MMT group. Therefore for moderate to severe CRSsNP patients, FESS+MMT therapy could be recommended as the preferred treatment.
Case-Control Studies ; Chronic Disease ; Endoscopy ; Humans ; Nasal Polyps ; surgery ; Prospective Studies ; Quality of Life ; Sinusitis ; surgery
5.Sperm origins and concentration do not impact the clinical outcomes in intracytoplasmic sperm injection cycles.
Cen YANG ; Ze-Hong ZHOU ; Dan-Ni ZHENG ; Xiao-Fei XU ; Jin HUANG ; Ying LIAN ; Jie QIAO
Asian Journal of Andrology 2018;20(5):454-458
In the present study, we evaluated the impact of sperm origins and concentration on the clinical outcomes of intracytoplasmic sperm injection (ICSI) cycles. A total of 1201 ICSI cycles were retrospectively analyzed for male azoospermia or oligozoospermia between January 2015 and December 2015 in the Peking University Third Hospital. Patients were divided into three groups (Group 1 vs Group 2/3; surgically extracted sperm vs ejaculated sperms): Group 1 included 343 ICSI cycles and Group 2 analyzed 388 cycles on semen with sperm concentration <5 × 106 ml-1 (severe oligozoospermia group). Group 3 included 470 cycles with sperm concentration between 5 × 106 ml-1 and 15 × 106 ml-1 (mild oligozoospermia group). Fertilization rates, clinical pregnancy rates, and live birth rates were analyzed and compared among groups of different semen origins and concentrations on the oocyte retrieval day. Group 2 showed a lower fertilization rate than Group 3 (62.9% ± 21.6% vs 66.8% ± 22.1%,P< 0.05). There were no statistically significant differences in clinical pregnancy rate per transfer (51.3%, 46.7%, and 50.0%, respectively), live birth rate per transfer (44.4%, 40.9%, and 41.4%, respectively), accumulative live birth rate (58.3%, 51.0%, and 52.1%, respectively), twin birth rate (18.4%, 10.6%, and 12.6%, respectively), and birth defects rate (0, 0.3%, and 0.2%, respectively) among three groups. The results of this study indicated that sperm origins and concentration do not impact the clinical outcomes in ICSI cycles.
Adult
;
Azoospermia/diagnosis*
;
Birth Rate
;
Female
;
Humans
;
Live Birth
;
Male
;
Oligospermia/diagnosis*
;
Pregnancy
;
Pregnancy Rate
;
Retrospective Studies
;
Semen Analysis
;
Sperm Injections, Intracytoplasmic/methods*
6.Prenatal Exposure to Perfluorooctane Sulfonate impairs Placental Angiogenesis and Induces Aberrant Expression of LncRNA Xist.
Gang CHEN ; Lin Lin XU ; Ye Fei HUANG ; Qi WANG ; Bing Hua WANG ; Ze Hua YU ; Qiao Mei SHI ; Jia Wei HONG ; Jing LI ; Li Chun XU
Biomedical and Environmental Sciences 2018;31(11):843-847
Alkanesulfonic Acids
;
toxicity
;
Animals
;
Female
;
Fluorocarbons
;
toxicity
;
Humans
;
Male
;
Mice
;
Neovascularization, Physiologic
;
drug effects
;
Pedigree
;
Placenta
;
blood supply
;
drug effects
;
metabolism
;
Pregnancy
;
Prenatal Exposure Delayed Effects
;
genetics
;
metabolism
;
physiopathology
;
RNA, Long Noncoding
;
genetics
;
metabolism
7. The neuroprotective effect of rhubarb on MCAO model rats
Chun-Xiao SUN ; Jia-Hui HUANG ; Li QIAO ; Jun-Jie LIU ; Yu-Heng TANG ; A-Juan XU ; Jing-Wen NIE ; Si-Ying HUANG ; Rui LUO ; Ze-Lin YANG ; Wen-Fang LAI ; Gui-Zhu HONG
Chinese Pharmacological Bulletin 2021;37(4):584-589
Aim To study the neuroprotective effect of rhubarb extract on MCAO model rats and explore its mechanism of action. Methods Forty-five SPF male Sprague-Dawley rats were randomly divided into sham group, MCAO group, and MCAO + rhubarb group. MCAO model was prepared by silk plug method, and rhubarb extract was administered at a concentration of 200 mg · kg
8.CRISPR/Cas9-mediated targeted gene correction in amyotrophic lateral sclerosis patient iPSCs.
Lixia WANG ; Fei YI ; Lina FU ; Jiping YANG ; Si WANG ; Zhaoxia WANG ; Keiichiro SUZUKI ; Liang SUN ; Xiuling XU ; Yang YU ; Jie QIAO ; Juan Carlos Izpisua BELMONTE ; Ze YANG ; Yun YUAN ; Jing QU ; Guang-Hui LIU
Protein & Cell 2017;8(5):365-378
Amyotrophic lateral sclerosis (ALS) is a complex neurodegenerative disease with cellular and molecular mechanisms yet to be fully described. Mutations in a number of genes including SOD1 and FUS are associated with familial ALS. Here we report the generation of induced pluripotent stem cells (iPSCs) from fibroblasts of familial ALS patients bearing SOD1 and FUS mutations, respectively. We further generated gene corrected ALS iPSCs using CRISPR/Cas9 system. Genome-wide RNA sequencing (RNA-seq) analysis of motor neurons derived from SOD1 and corrected iPSCs revealed 899 aberrant transcripts. Our work may shed light on discovery of early biomarkers and pathways dysregulated in ALS, as well as provide a basis for novel therapeutic strategies to treat ALS.
Amyotrophic Lateral Sclerosis
;
genetics
;
metabolism
;
therapy
;
Cell Line
;
Clustered Regularly Interspaced Short Palindromic Repeats
;
Genetic Therapy
;
Genome-Wide Association Study
;
Humans
;
Induced Pluripotent Stem Cells
;
metabolism
;
Mutation, Missense
;
RNA-Binding Protein FUS
;
genetics
;
metabolism
;
Superoxide Dismutase-1
;
genetics
;
metabolism
9.Modeling xeroderma pigmentosum associated neurological pathologies with patients-derived iPSCs.
Lina FU ; Xiuling XU ; Ruotong REN ; Jun WU ; Weiqi ZHANG ; Jiping YANG ; Xiaoqing REN ; Si WANG ; Yang ZHAO ; Liang SUN ; Yang YU ; Zhaoxia WANG ; Ze YANG ; Yun YUAN ; Jie QIAO ; Juan Carlos IZPISUA BELMONTE ; Jing QU ; Guang-Hui LIU
Protein & Cell 2016;7(3):210-221
Xeroderma pigmentosum (XP) is a group of genetic disorders caused by mutations of XP-associated genes, resulting in impairment of DNA repair. XP patients frequently exhibit neurological degeneration, but the underlying mechanism is unknown, in part due to lack of proper disease models. Here, we generated patient-specific induced pluripotent stem cells (iPSCs) harboring mutations in five different XP genes including XPA, XPB, XPC, XPG, and XPV. These iPSCs were further differentiated to neural cells, and their susceptibility to DNA damage stress was investigated. Mutation of XPA in either neural stem cells (NSCs) or neurons resulted in severe DNA damage repair defects, and these neural cells with mutant XPA were hyper-sensitive to DNA damage-induced apoptosis. Thus, XP-mutant neural cells represent valuable tools to clarify the molecular mechanisms of neurological abnormalities in the XP patients.
DNA Damage
;
DNA Repair
;
DNA-Binding Proteins
;
genetics
;
metabolism
;
Female
;
Humans
;
Induced Pluripotent Stem Cells
;
metabolism
;
pathology
;
Male
;
Models, Biological
;
Mutation
;
Neural Stem Cells
;
metabolism
;
pathology
;
Xeroderma Pigmentosum
;
genetics
;
metabolism
;
pathology